These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24968896)

  • 21. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
    McDermott MS; Chumanevich AA; Lim CU; Liang J; Chen M; Altilia S; Oliver D; Rae JM; Shtutman M; Kiaris H; Győrffy B; Roninson IB; Broude EV
    Oncotarget; 2017 Feb; 8(8):12558-12575. PubMed ID: 28147342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
    Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
    Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
    Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
    Dong M; Rice L; Lepler S; Pampo C; Siemann DW
    Anticancer Res; 2010 Nov; 30(11):4405-13. PubMed ID: 21115886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide.
    Varricchio L; Migliaccio A; Castoria G; Yamaguchi H; de Falco A; Di Domenico M; Giovannelli P; Farrar W; Appella E; Auricchio F
    Mol Cancer Res; 2007 Nov; 5(11):1213-21. PubMed ID: 18025264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
    Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
    Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
    Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
    J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
    Chu I; Arnaout A; Loiseau S; Sun J; Seth A; McMahon C; Chun K; Hennessy B; Mills GB; Nawaz Z; Slingerland JM
    J Clin Invest; 2007 Aug; 117(8):2205-15. PubMed ID: 17627304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
    Huang Y; Jiang D; Sui M; Wang X; Fan W
    Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
    Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
    Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
    Hou JY; Rodriguez-Gabin A; Samaraweera L; Hazan R; Goldberg GL; Horwitz SB; McDaid HM
    PLoS One; 2013; 8(2):e54103. PubMed ID: 23390495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
    Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR; Bradley SV; Fuchshuber S; Conover CA
    Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.